Country: Malta
Language: English
Source: Medicines Authority
CEFTRIAXONE SODIUM
DALI Pharma GmbH Brehmstrasse 56, 40239, Dusseldorf,, Germany
J01DD04
CEFTRIAXONE SODIUM 250 mg
POWDER FOR SOLUTION FOR INJECTION
CEFTRIAXONE SODIUM 250 mg
POM
ANTIBACTERIALS FOR SYSTEMIC USE
Licence number in the source country: NOT APPLICAPABLE
Authorised
2021-08-19
Page 1 of 13 PACKAGE LEAFLET: INFORMATION FOR THE USER CEFTRIAXONE DALI PHARMA 250 MG POWDER FOR SOLUTION FOR INJECTION CEFTRIAXONE DALI PHARMA 500 MG POWDER FOR SOLUTION FOR INJECTION CEFTRIAXONE DALI PHARMA 1 G POWDER FOR SOLUTION FOR INJECTION _Ceftriaxone _ READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. − Keep this leaflet. You may need to read it again. − If you have any further questions, ask your doctor, pharmacist or nurse. − Ifyou get any side effects,talk to your doctor, pharmacist or nurse.This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Ceftriaxone DALI Pharma is and what it is used for 2. What you need to know before you are given Ceftriaxone DALI Pharma 3. How Ceftriaxone DALI Pharma is given 4. Possible side effects 5. How to store Ceftriaxone DALI Pharma 6. Contents of the pack and other information 1. WHAT CEFTRIAXONE DALI PHARMA IS AND WHAT IT IS USED FOR Ceftriaxone DALI Pharma contains the active substance ceftriaxone which is an antibiotic given to adults and children (including newborn babies). It works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins _. _ Ceftriaxone DALI Pharma is used to treat infections of: − the brain (meningitis); − the lungs; − the middle ear; − the abdomen and abdominal wall (peritonitis); − the urinary tract and kidneys; − bones and joints; − the skin or soft tissues; − the blood; − the heart. Ceftriaxone DALI Pharma can be given: − to treat specific sexually transmitted infections (gonorrhoea and syphilis); − to treat patients with low white blood cell counts (neutropenia) who have fever due to bacterial infection; − to treat infections of the chest in adults with chronic bronchitis; − to treat Lyme disease (caused by tick bites) in adults and children including newborn babies from 15 days of age; − to prevent infections during surgery. Page Read the complete document
Page 1 of 20 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ceftriaxone DALI Pharma 250 mg Powder for Solution for Injection Ceftriaxone DALI Pharma 500 mg Powder for Solution for Injection Ceftriaxone DALI Pharma 1 g Powder for Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ceftriaxone DALI Pharma 250 mg Powder for Solution for Injection Each vial contains 250 mg of ceftriaxone as ceftriaxone sodium. Each vial contain 20.7 mg (0.9 mmol) sodium / vial. Ceftriaxone DALI Pharma 500 mg Powder for Solution for Injection Each vial contains 500 mg of ceftriaxone as ceftriaxone sodium. Each vial contain 41.5 mg (1.8 mmol) sodium / vial. Ceftriaxone DALI Pharma 1 g Powder for Solution for Injection Each vial contains 1 g of ceftriaxone as ceftriaxone sodium. Each vial contain 82.9 mg (3.6 mmol) sodium / vial. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for solution for injection. Almost white or yellowish crystalline powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ceftriaxone DALI Pharma is indicated for the treatment of the following infections in adults and children including term neonates (from birth): − bacterial meningitis; − community acquired pneumonia; − hospital acquired pneumonia; − acute otitis media; − intra-abdominal infections; − complicated urinary tract infections (including pyelonephritis); − infections of bones and joints; − complicated skin and soft tissue infections; − gonorrhoea; − syphilis; − bacterial endocarditis. Page 2 of 20 Ceftriaxone DALI Pharma may be used: − for treatment of acute exacerbations of chronic obstructive pulmonary disease in adults; − for treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age; − for pre-operative prophylaxis of surgical site infections; − in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection; − in the t Read the complete document